AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03099005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: vaporization of cannabis
Study NCT04254458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal densitometry
Description: Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
Study NCT03925285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
Study NCT04402034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application of tele-rehabilitation
Description: Individuals that will perform the virtual reality intervention.
Study NCT03672578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loss-frame
Description: loss frame label
Study NCT03672578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gain-frame
Description: gain frame label
Study NCT03672578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text-only
Description: text-only label
Study NCT03672578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icon
Description: label with icon and text
Study NCT05295316 — intervention group
Intervention type: OTHER
Intervention: Life Stressor Checklist Revised (LSC-R) (Appendix 1)
Description: Evaluation of stress factor as risk factor for fibromyalgia development
Study NCT00818181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: AL0206st
Study NCT06441526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-tumour necrosis factor α antibodies
Description: Biological drug
Study NCT06441526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advancement plasty
Description: Surgical closure of the internal opening
Study NCT00628173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AGV implantation
Study NCT02774551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention group
Description: 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
Study NCT02088788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Board
Description: Also has radio-dense pelvic shielding
Study NCT02088788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Board
Description: Radio-lucent armboard for radial access with radio-dense drape across pelvis
Study NCT01230853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: A
Description: Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
Study NCT01230853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator B
Description: Placebo Matching Placebo Infusion
Study NCT01230853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator B
Description: Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
Study NCT01230853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator A
Description: Placebo Matching Placebo Infusion
Study NCT01083628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Depression with MoodText
Description: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
Study NCT01083628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group CBT for Depression
Description: Standard group CBT for depression using BRIGHT manual
Study NCT03792386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guidance with fluoroscopic confirmation
Description: the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
Study NCT03792386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic guidance with ultrasonographic confirmation.
Description: After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced \~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
Study NCT04582981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and raltitrexed
Description: Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
Study NCT04582981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5mg qd monotherapy
Study NCT03697434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care referral
Description: Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
Study NCT03156127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-UPS 5 mg tablet, Inisia 5 mg tablet
Description: Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
Study NCT03156127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR-UPS 5 mg tablet, Inisia 5 mg tablet
Description: Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
Study NCT05298982 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early activity and Mobilisation Intervention
Description: The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: IV and subcutaneous injection
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and subcutaneous injection
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus
Description: The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolic mofetil was administered as 750 mg twice per day orally
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolic mofetil was administered as 750 mg twice per day orally
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
Study NCT00617604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroids
Description: Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
Study NCT00154336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Study NCT00154336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT00154336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study NCT00154336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imatinib Placebo
Study NCT00786812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nilotinib
Study NCT00420602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Over the counter DHA/EPA dietary supplementation
Description: 1000 mg/day DHA/EPA
Study NCT01193881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01193881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01193881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01193881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02530983 — intervention group
Intervention type: OTHER
Intervention: Mayo Clinic Upper Digestive Disease Survey on Paper
Description: Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
Study NCT02530983 — intervention group
Intervention type: OTHER
Intervention: Upper Digestive Disease (UDD Monitor) App
Description: Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1
Study NCT02627755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aScope®
Description: we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
Study NCT02627755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope®
Description: use of Glidescope® in conventional manner to facilitate endotracheal intubation
Study NCT02627755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope®
Description: use of Glidescope® in conventional manner to facilitate endotracheal intubation
Study NCT01854645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI
Description: GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
Study NCT01854645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI
Description: GP MDI administered as two puffs BID
Study NCT01854645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI
Description: FF MDI administered as two puffs BID
Study NCT01854645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
Description: Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Study NCT01854645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Inhaled placebo administered as two puffs BID
Study NCT02326714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
Study NCT02326714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo auricular acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
Study NCT01223521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate intrauterine contraception
Description: A Cu-IUD or LNG-IUS is inserted after abortion.
Study NCT03050996 — intervention group
Intervention type: PROCEDURE
Intervention: robotic radical prostatectomy
Description: Urodynamic evaluation during robotic radical prostatectomy
Study NCT02075411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block
Study NCT02075411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block
Study NCT02075411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous perineural infusion catheter
Description: Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
Study NCT02075411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous perineural infusion catheter
Description: Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
Study NCT03178968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 3 immersion times in orange juice were investigated
Study NCT04687761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle
Study NCT04687761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
Study NCT04687761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib 40 mg/daily oral, days, 8 to 28
Study NCT04687761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
Study NCT04687761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
Study NCT04687761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib 40 mg/daily oral, days 8 to 28
Study NCT03533595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Barbed
Description: Barbed Suture
Study NCT01109836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and lifestyle intervention
Description: Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
Study NCT00824824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%-timolol 0.5%
Description: BID OU for 6 weeks
Study NCT00824824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%-0.5% timolol 0.5
Description: BID OU for 6 weeks
Study NCT00979251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate
Description: Oseltamivir Phosphate, q8h
Study NCT00979251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-8902
Description: Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
Study NCT02717754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
Study NCT02717754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oseltamivir matched placebo will be administered intravenous for 5 days.
Study NCT03430219 — intervention group
Intervention type: DEVICE
Intervention: Subchondroplasty Procedure
Description: AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
Study NCT00617539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00617539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT03666000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azer-cel
Description: Infusion of Allogeneic Anti-CD19 CAR T cells
Study NCT03666000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT03666000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT03666000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Specified dose on specified days
Study NCT03666000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Specified dose on specified days
Study NCT03952338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food coupons
Description: Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
Study NCT03952338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition skill-building
Description: Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
Study NCT03691935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
Study NCT03691935 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
Study NCT01789099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 synthetic peptide vaccine and GM-CSF
Study NCT02294435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
Study NCT02294435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unitary Manifold
Description: Unitary Manifold Endovascular stent graft system
Study NCT04605445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 visit root canal treatment (endodontics)
Description: Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.